Main navigation

• Home
• Our medicines
• Diseases and conditions
• Community support
• Help affording your medicines
• Research & development
• Healthcare professionals
• Careers
• About AstraZeneca US
  • Investors
  • Our company
  • AZ on the issues
  • Responsible business
  • Newsroom
    • Media resources
    • All news
    • Corporate news
    • Financial news
    • Product news
    • Research news
  • US web sites
  • Contact us

You are here

• Home
• About AstraZeneca US
• Newsroom

• News

The following shows headlines of all news articles published within 12-months, starting from most recent.

• Pages
• Previous
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• Next

• • Mar 29, 2009
  • CRESTOR® reduced CV risk in patients achieving low LDL and hsCRP targets in new JUPITER analysis  
• • Mar 24, 2009
  • AstraZeneca calls on all Americans to join US AGAINST ATHERO to fight the nation’s number one killer  
• • Mar 14, 2009
  • AstraZeneca applauds appointment of new FDA Commissioner  
• • Mar 9, 2009
  • AstraZeneca receives prestigious CEO Cancer Gold Standard™ reaccreditation  
• • Feb 27, 2009
  • FDA approves SYMBICORT® for Chronic Obstructive Pulmonary Disease (COPD)  
• • Feb 23, 2009
  • AstraZeneca’s partner, MAP Pharmaceuticals, announces Phase 3 study of Unit Dose Budesonide in children with asthma did not meet primary endpoints  
• • Feb 23, 2009
  • AstraZeneca announces SEROQUEL XR is now available to treat bipolar depression  
• • Feb 19, 2009
  • CRESTOR cuts risk of stroke by nearly half in JUPITER study  
• • Feb 19, 2009
  • AstraZeneca, American Heart Association pay it forward to the city of New Orleans with donation to rebuild city walking path  
• • Feb 17, 2009
  • AstraZeneca applauds health provisions in economic stimulus bill  

• Pages
• Previous
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• Next

Page tools

• Print
• Bookmark this page
• Subscribe to RSS news feed